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Dicer and Drosha are key enzymes in the miRNA-processing
pathway which is altered in many human cancers.
We analyzed Dicer and Drosha expression levels by quantita-
tive PCR in 151 patients with monoclonal gammopathies: 102
symptomatic myeloma patients, 23 smoldering myelomas
and 26 monoclonal gammopathy of undetermined signifi-
cance. We found that Dicer expression values were signifi-
cantly higher in monoclonal gammopathy of undetermined
significance than in smoldering myelomas and symptomatic
myeloma (mean ± SD, 0.84±0.36 vs. 0.60±0.23 and 0.62±0.51;
P<0.01). Moreover, the median progression-free survival was
significantly longer in symptomatic myeloma patients with
high expression of Dicer (not reached vs. 23.6 months;
P=0.02). By contrast, no differences in the expression of
Drosha among these groups of patients were observed.
Our data suggest that Dicer expression may play an impor-
tant role in the progression and prognosis of monoclonal gam-
mopathies.
(Clinicaltrials.gov identifier: NCT00461747 for MM patients under
65 years of age and NCT00443235 for MM patients over 65 years
of age)
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ABSTRACT
Introduction 
MicroRNAs (miRNAs) are small non-coding RNAs that
regulate gene expression at the post-transcriptional level and
are involved in critical biological processes. MiRNA process-
ing starts in the nucleus, where long endogenous double-
stranded RNA segments (pri-miRNA) are cut into short hair-
pin-shaped double-stranded RNA precursors (pre-miRNA)
by the RNAase III enzyme Drosha. Pre-miRNAs then move
to the cytoplasm, where they are cleaved by Dicer to yield
mature miRNAs, which produce mRNA degradation or
translational repression after being activated through the
RNA-induced silencing complex (RISC). We and other
researchers have shown abnormal expression of miRNAs in
many types of human tumors, including multiple myeloma
(MM).1-6 The potential role of Dicer and Drosha as master
regulators of the RNA interference machinery in tumorigen-
esis has also been investigated in several malignancies.7-11
Low levels of Dicer and Drosha expression were associated
with advanced tumor stage and suboptimal tumor cytore-
duction, respectively, in ovarian cancer.9 Likewise, a low
level of these enzymes has been found in high-risk neurob-
lastoma tumors with poor outcome.11 Similar observations
have been made in lung cancer in which upregulation of
Dicer was observed in precursor lesions while decreased lev-
els were found in invasive lung adenocarcinoma.7 By con-
trast, in prostate cancer a high level of Dicer expression was
associated with metastatic disease.12 As far as hematologic
malignancies is concerned, Dicer expression has only been
investigated in acute myeloid leukemia.13
These findings prompted us to investigate Dicer and
Drosha expression levels in patients with monoclonal gam-
mopathies. This term covers a wide spectrum of plasma cell
(PC) disorders: from the pre-malignant conditions, mono-
clonal gammopathy of undetermined significance (MGUS) to
the smoldering myeloma (SMM) and, finally, the more
advanced and aggressive disease, the symptomatic multiple
myeloma. This progressive model of transformation pro-
vides a unique opportunity to investigate the potential role of
Dicer and Drosha in the pathogenesis of monoclonal gam-
mopathies. In addition, we have also investigated the corre-
lation of Dicer expression with cell cycle distribution and dis-
ease outcome in symptomatic multiple myeloma treated
according to the Spanish Pethema trial GEM–2005.14
Design and Methods
The study included 151 patients: 102 symptomatic mul-
tiple myeloma, 23 smoldering myeloma and 26 mono-
clonal gammopathy of undetermined significance cases,
and 5 healthy donors as normal controls. All patients pro-
vided written informed consent in accordance with the
Declaration of Helsinki, and the research ethics committee
of the University Hospital of Salamanca approved the
study. Symptomatic multiple myeloma patients were
treated according to the Spanish Pethema trial GEM-2005
(ClinicalTrials.Gov: NCT00461747 for MM patients under
65 years of age and NCT00443235 for MM patients over
65 years of age.14
CD138-positive plasma cell (PC) isolation was per-
formed in all diagnostic bone marrow samples. The purity
was above 95% in the smoldering myeloma and multiple
myeloma and 90% in monoclonal gammopathy of unde-
termined significance and healthy donors. Total RNA was
extracted from tumor plasma cells using an RNEasy Mini
Kit (Qiagen, Valencia, USA) following the manufacturer's
protocol. RNA quality and quantity were assessed with
the RNA Nano LabChip (Agilent Tech. Inc., Palo Alto, CA,
USA). The retrotranscription reaction was performed with
a High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems Foster City, CA, USA) according to the manu-
facturer’s recommendations. Finally, real-time quantitative
PCR was performed using TaqMan gene expression assay
kits (Applied Biosystems Foster City, CA, USA):
Hs_00229023 for Dicer, Hs_00203008 for Drosha and
Hs00245445_m1 for ABL as a control gene. Relative gene
expression was calculated by the 2-DCt method, DCt=Ct(gene)
– Ct(ABL).15 The data were presented as log10 values of the
relative quantity of each gene. 
In addition, we used miRNA expression profile data
assessed by quantitative PCR from a previously published
manuscript; data  available for 27 out of the 102 sympto-
matic multiple myeloma patients (GEO accession number:
GSE16558).2
The cell cycle was analyzed by multiparametric flow
using a CD38/CD138 propidium iodide double-staining
technique, as previously described16 in a subset of 80
symptomatic multiple myeloma patients.
The Mann-Whitney U test was used to identify statisti-
cally significant differences between groups. Progression-
free survival (PFS) and overall survival (OS) distribution
curves were plotted using the Kaplan-Meier method; the
log rank test was used to estimate the statistical signifi-
cance of differences between the curves. All statistical
analyses were conducted using SPSS (version 15.0; SPSS
Inc., Chicago, IL, USA).
Results and Discussion
The expression values of Dicer were significantly higher
in monoclonal gammopathy of undetermined significance
than in smoldering myeloma (mean±SD, 0.84±0.36 vs.
0.60±0.23; P=0.013) and symptomatic multiple myeloma
(mean±SD, 0.84±0.36 vs. 0.62±0.51; P=0.007). However,
no differences were found between smoldering myeloma
and multiple myeloma (Figure 1). Dicer expression level in
normal plasma cells (NPC) from healthy donors was very
similar to monoclonal gammopathy of undetermined sig-
nificance (mean±SD, 0.92±0.72 vs. 0.84±0.36). No relevant
differences were found in Drosha expression between
these entities, although the series of multiple myeloma
patients analyzed was rather short (n=49). These data
show that monoclonal gammopathy of undetermined sig-
nificance, a pre-malignant condition, displays higher levels
of Dicer than both smoldering and symptomatic myelo-
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Figure 1. Expression of Dicer and Drosha by real-time quantitative PCR in Normal plasma cells (NPC), monoclonal gammopathy of undeter-
mined significance (MGUS), smoldering myeloma (SMM) and symptomatic multiple myeloma (MM) patients. Relative values were calculated
by the 2-DCt method (DCt = Ct(Gene)– Ct(ABL)). The ABL gene was used as a control gene.
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ma, and very similar to those in normal plasma cells.
These findings are concordant with those described in
lung cancer, which showed upregulation of Dicer in the
precursor lesions and reduced expression in the more
aggressive stages,7 as well as in ovarian cancer, with low
Dicer mRNA levels in advanced disease.
To validate these results, we evaluated Dicer expression
levels generated by Affymetrix microarray platform. We
used data for 60 symptomatic multiple myeloma patients
and normal plasma cells from 5 healthy controls of bone
marrow (data are available to the public on the NIH GEO
[http://www.ncbi.nlm.nih.gov/geo/] under accession
number GSE16558)2 and a set of 20 monoclonal gam-
mopathy of undetermined significance and 33 smoldering
myeloma samples also analyzed in our institution (JF San
Miguel, unpublished data, 2011). All the samples had been
analyzed with the Human Gene 1.0 ST Array. We
observed that the expression values of Dicer were signifi-
cantly higher in normal plasma cells, monoclonal gam-
mopathy of undetermined significance and smoldering
myeloma than in symptomatic multiple myeloma
(P=1.8¥10-5, P=5.2¥10-6, P=5¥10-7, respectively). No differ-
ences were found between monoclonal gammopathy of
undetermined significance and smoldering myeloma
(Figure 2). Maybe the different samples used for this com-
parison can explain these slightly different findings.
Nevertheless, these results confirm that Dicer expression
was down-regulated in symptomatic multiple myeloma
compared to normal plasma cells and monoclonal gam-
mopathy of undetermined significance. 
A global increase of microRNA expression by Dicer
upregulation has been suggested in several tumors.11,12 To
explore this possibility, we reviewed our recently pub-
lished data on miRNA expression profile assessed by
quantitative PCR in order to compare this among high and
low Dicer multiple myeloma patients (n=27).2 To define
high and low Dicer expression levels, we selected a cut-off
value of 0.66, since this was close to the median Dicer
M.E. Sarasquete et al.
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Figure 2. Expression of Dicer by Human Gene 1.0 ST Affymetrix
Array in normal plasma cells (NPC), monoclonal gammopathy of
undetermined significance (MGUS), smoldering myeloma (SMM)
and symptomatic multiple myeloma (MM) patients.
Table 1. List of miRNAs significantly up-regulated in the group of MM
patients showing high levels of Dicer expression (P<0.01). 
MiRNA                                                      P value
miR-7a                                                                    0.006
miR-7b                                                                    0.007
miR-7d                                                                    0.002
miR-7e                                                                     0.01
miR-7g                                                                    0.005
miR-93                                                                    0.009
miR-142-3p                                                            0.007
miR-142-5p                                                            0.011
miR-218                                                                  0.015
miR-223                                                                  0.009
miR-301                                                                  0.005
miR-26b                                                                  0.003
miR-103                                                                  0.001
miR-125a                                                                0.006
miR-497                                                                  0.001
miR-30c                                                                  0.006
miR-206                                                                  0.009
miR-371                                                                  0.009
miR-198                                                                  0.009
miR-28                                                                    0.005
miR-32                                                                    0.003
miR-149                                                                  0.007
miR-196b                                                                0.013
miR-325                                                                  0.008
miR-328                                                                  0.002
miR-342                                                                 0.0005
miR-500                                                                  0.008
miR-139                                                                  0.008
miR-145                                                                  0.004
miR-425                                                                  0.013
miR-591                                                                  0.008
miR-601                                                                  0.001
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Figure 3. Progression-free survival in symptomatic multiple myeloma
patients (n=85) with respect to Dicer gene expression level. 
expression in the multiple myeloma samples. We ana-
lyzed the 368 miRNA, previously normalized with the
median values of RNU44-RNU48 control miRNA (Delta
CT values). We found significant differences (P<0.01) in 32
miRNAs (8.7%), whose expression profile displayed high-
er values in the group of patients with high Dicer levels
(Table 1). 
Zhou et al. have recently reported that the silencing of
Dicer is associated with significantly enhanced G0– to G1–
phase accumulation and greatly increased apoptosis.17 To
assess whether the high levels of Dicer expression are
related to cell-cycle activation, we compared the distribu-
tion of plasma cells among G0-G1, S and G2-M phases in
the symptomatic multiple myeloma patients divided into
two groups: high versus low levels of Dicer expression. We
failed to find differences in cell-cycle distribution between
the two groups, and there was no cell-cycle arrest in those
patients with the lowest expression levels of Dicer; these
results apparently differ from those of Zhou et al. but the
discrepancies can be explained by differences in the sam-
ple material analyzed (cell lines and fresh tumor cells from
patients), and also because the silencing in vitro of Dicer
expression may have different effects than its pathophys-
iological downregulation.
Finally, we analyzed the impact of Dicer expression lev-
els in the clinical outcome of 85 multiple myeloma
patients treated according to the GEM05 trial. We found
no significant differences in the clinical or biological fea-
tures of multiple myeloma patients between the high and
low Dicer expression level groups. Additionally, we eval-
uated the expression of Dicer according to the ploidy sta-
tus, and we could not find any noteworthy differences
among the hyperdiploid and non-hyperdiploid patients.
The most relevant genetic abnormalities (IGH transloca-
tions, RB and P53 deletions) were also evaluated, but there
was no association between these genetic features and
Dicer status. However, the median progression-free sur-
vival was significantly longer in multiple myeloma
patients with a high expression level of Dicer (not reached
vs. 23.6 months; P=0.02) as compared with those with
weak Dicer expression (Figure 3). When we selected only
those patients under 65 years of age who received high-
dose melphalan followed by autologous stem cell trans-
plantation, progression-free survival tended to be longer in
patients with high levels of Dicer (not reached vs. 26),
although the differences were not statistically significant
probably because of the small number of patients (data not
shown). As mentioned above, the prognostic impact of the
enzymes involved in the miRNA processing machinery
has been widely explored in solid tumors.7-9;11 By contrast,
to the best of our knowledge, the prognostic influence of
Dicer expression in hematologic malignancies has only
been analyzed in a group of 71 acute myeloid leukemia
patients, in whom no influence in outcome was appar-
ent.13
Our results show that Dicer expression levels are up-
regulated in monoclonal gammopathy patients with a pre-
malignant condition compared with smoldering and
symptomatic multiple myeloma. Moreover, in line with
this finding, we observed that in symptomatic multiple
myeloma patients the progression-free survival is longer
for cases with high levels of Dicer. 
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